CD160 is a human NK-cell activating receptor, also expressed on T-cell subsets. Here we examined 
Introduction

CD160 is an immunoglobulin (Ig)
neg . 5 A minor population of CD4+ T-cells also express CD160. 6 CD160 mRNA expression was shown to be highly restricted to NK cells and not detected in myeloid and B-cell lines by northern blot analysis. 5 Outside of the immune system, CD160 is expressed on endothelial cells of neoangiogenic microvessels at the periphery of tumors. 7 NK cells play a key role in innate immunity with potent cytolytic activity against virally infected and tumor cells. 8 NK cell activity is regulated by inhibitory and activatory receptors expressed at the cell surface and their interaction with associated ligands. 9 CD160 binds to MHC class Ia and Ib with low affinity 10 and triggers cytotoxic function in peripheral blood NK cells, as well as cytokine production, including interferon (IFN)-γ, tumor necrosis factor (TNF)-α, and interleukin (IL)-6. 11, 12 Only a limited selection of human activating NK cell receptors have been demonstrated to induce cytokine production and release in addition to cytotoxicity. 13 The phosphatidylinositol 3-kinase (PI3K) signaling molecule is required for CD160-mediated cytokine release, with involvement of the signaling molecules Syk and ERK upstream and downstream of PI3K, respectively.
14 Recent work has shown CD160 expression in malignant human B-cells. 15 CD160 expressed on the surface of B-cell chronic lymphocytic leukemia (CLL) mimicked CD160 functions in normal NK and T-cells: cellular activation; upregulation of BCL-2, BCL-XL , improved in vitro cell survival; and cytokine production, specifically, IL-6 and IL-8. PI3K/Akt signaling was required for CD160-mediated functions in CLL cells. 15 Similar "aberrant" expression of a signaling molecule, CD3-receptorassociated protein tyrosine kinase, zeta-associated protein-70 (ZAP-70), was reported in CLL. 16, 17 Like CD160, ZAP-70 was initially described exclusively in T-cells and NK cells, 18 but subsequently detected in mature and immature human B-lymphoid malignancies, [19] [20] [21] as well as normal murine and human B-cells. 22, 23 For personal use only. on . by guest www.bloodjournal.org From
In this paper, we have investigated normal and malignant human B-cells for expression of CD160. This extensive study has established that the NK cell receptor antigen CD160 shows restricted expression in the B-cell lineage to malignant versus normal B-cells. Moreover, the varying expression of CD160 can be exploited diagnostically, as shown in test and validation sets consisting of over 970 cases of B-cell lymphoproliferative disorders (B-LPD).
Material and methods
Patients and samples
This study involved a test cohort of 811 consecutive patient samples referred for investigation of B-LPD between 2002 and 2008, in which a complete analysis was performed. Standard diagnostic criteria were used to establish the diagnosis of CLL (n=600), mantle cell lymphoma (MCL, n=34), hairy cell leukemia (HCL, n = 32) and other B-LPDs (n=145, incorporating acute lymphoblastic leukemia (ALL), and other mature B-cell malignancies). 24, 25 Correlation with bone marrow aspirate & trephine, lymph node and spleen by flow cytometry, histology and karyotyping was performed when required.
The validation cohort included 163 consecutive cases of mature B-LPD (CLL n=113, MCL n=8, HCL n=3, other B-LPD n=39). The median fluorescence intensities (MFI) for malignant populations given in this paper are generated from the validation cohort.
Non-diagnostic analyses were approved by the National Research Ethics Service, East London and the City HA Local Research Ethics Committee and written informed consent was obtained in accordance with the Declaration of Helsinki. Following informed consent, control blood samples were taken from normal healthy donors (n=30), donor bone marrow aspirates (n=6) and cord blood sampling (n=5).
Where possible tissue perfusion samples were obtained including spleen (n=5), lymph-node biopsy (n=5) and tonsil biopsies (n=4) from both healthy donors and patients.
Immunophenotypic Analysis using CD160 Flow Cytometric Assay (CD160FCA)
The five-color CD160 Flow Cytometric Assay (CD160FCA) incorporated CD2-FITC (Clone S5. Combining these parameters -{mini CLL score x CD23r} -allowed the immunophenotypic data to be expressed as a single numerical value, the "diagnostic discriminant".
RNA extraction, reverse transcription, cDNA amplification (RT-PCR) and sequencing for CD160
PBMC from EDTA anticoagulated venous blood obtained from healthy donors and patients were isolated by density gradient centrifugation (Lymphoprep, Amersham Bioscience, UK). Fresh CD19 + B cells were isolated using a magnetic-activated cell sorter (MACS) and a CD19 + cell isolation kit according to the manufacturers' recommendations (MiltenyiBiotec, Bergish-Gladbach, Germany).
CD19
+ cell purity was shown to be >97%.
Total RNA was isolated using the Trizol reagent according to the manufacturer's instructions (Invitrogen, Paisley, UK). For each reverse transcription, 5µg of RNA were used. Reverse transcription was performed using 500ng of an oligo-dT primer (Invitrogen, Paisley, UK) and the superscript first strand synthesis kit (Invitrogen) in a total volume of 20µl. Specific primers for the amplification of CD160 (GenBank accession: NM_007053) cDNA were designed on the basis of published sequences.
The CD160 primers were as follows: BY01 (5'-TGCAGGATGCTGTTGGAACCC-3') (forward) and BY3UN (5'-CCTGTGCCCTGTTGCATTCTTC-3') (reverse). β-actin cDNA amplification was For personal use only. on September 14, 2017. by guest www.bloodjournal.org From dehydrated using ethanol followed by xylene and finally mounted with a xylene based DPX mount (Sigma, UK).
Statistical analysis
Standard approaches were used to calculate diagnostic indices of sensitivity and specificity. Statistical analysis was performed using Stats Direct v2.7.6 (StatsDirect Ltd, Cheshire, UK) and GraphPad PRISM 5 for Macintosh (GraphPad software, CA, USA). The diagnostic odds ratio is used as a single measure of efficacy of a diagnostic test which is unaffected by prevalence and effectively compares the odds of positivity in disease (sensitivity) relative to the odds of positivity in patients without the disease (1-specificity). The ratio can range from 0 to infinity, larger numbers indicating a better test performance. Indices are quoted as the statistic (95% confidence interval). When reporting the MFI, indices are quoted as the mean (95% confidence interval of the mean).
Results
Expression of CD160 on normal B-cells
In normal peripheral blood, CD160 protein is expressed on the cell membrane of 15 -20 % of CD2 To confirm the flow cytometric protein expression data, total RNA was extracted from highly purified CD19 + B-cells. As expected, CD160 transcript was detected in all control mononuclear cell (MNC) fractions (representing normal NK and T-cells), but was absent from purified normal B-cells ( Figure   3C ), Pre-B-ALL ( Figure 3D ), follicular lymphoma ( Figure 3E ) and MCL ( Figure 3F Throughout the study period CD160 analysis was performed on a number of cases of reactive polyclonal B cell lymphocytoses -in all cases the polyclonal B-cells were negative for CD160 expression.
For
Immunohistochemistry with CD160 in CLL, HCL and MCL
To further establish the expression of CD160 in malignant B-cells, immunohistochemistry staining of CD160 was performed using paraffin embedded histological sections and tissue microarrays (Figure 4 ).
Of all 88 TMA CLL cases, 85 (96.5%) were positive for CD160 (Figure 4D-F) . Similarly, 2 out of 2 cases of HCL (a trephine biopsy, Figure 4J ; a splenic biopsy, figure 4K-L) were positive for CD160 and showed a stronger expression than in CLL, confirming the results observed by flow cytometry. Of 97 MCL cases on TMAs, only 3 cases (3%) were positive for CD160 (Figure 4 G-I) .
Implementing the CD160FCA into clinical diagnostics
From a test cohort of 811 consecutive cases of mature B-LPD, a "mini CLL score" was developed Although MCL is typically CD23 negative, in the test cohort 11/34 (32 %) cases of MCL expressed CD23 (with all cases were confirmed to be MCL by G banding, fluorescence in-situ hybridization and/or histology), which is similar to other reports. 26, 27 In contrast, 598/600 (>99 %) cases of CLL were CD23 + . As the CD23 percentage positivity in MCL is lower than in CLL, we investigated the ratio of the percentage CD23 to CD5 expression on the malignant B cells (referred to as, CD23r) as a parameter to differentiate CLL from CD23 + MCL. In CD23 + MCL cases, 87% had a ratio of 0.80 or less, with 85% of these having a ratio of 0.50 or less. In contrast, of the CLL cases analyzed (n = 431), CD23r was greater than 0.80 in 97%, and only 0.8% of CLL patients had a ratio of 0.50 or less.
The disease-specific expression of the CD5/CD23/CD160 combination was also investigated using the CD160FCA methodology in a validation cohort (n=163). This confirmed CD160 positivity in CLL (107/113 cases, 95%) and the utility of the mini CLL score: 3 was diagnostic of CLL and excluded all Figure 5B ).
Further differentiation between B-LPDs was achieved by multiplying the mini score by CD23r to give a single numerical value, the diagnostic discriminant ( Figure 5C ). The diagnostic discriminant allowed immunophenotypic separation of CLL from MCL (including leukemic CD23 + MCL), HCL and other CD5+ B-LPD.
Monoclonal B-cell lymphocytosis
Monoclonal B-cell lymphocytosis (MBL) has been used to describe asymptomatic patients with a monoclonal lymphocytosis but <5000 B-cells/μl with a CLL phenotype. 24 Within the validation cohort, 13.3% (16/113) of CLL cases had a lymphocyte count <5x10 9 /L, of which 15/16 cases expressed the CD160 antigen. The mean percentage of CD160 expression in these 16 cases was 59.5%, similar to that of all CLL in the validation cohort (54.6%) (Supplemental Figure 1A) . Similarly, the MFI of CD160 in the 16 cases was almost identical to that of all CLL within the validation cohort (537.6 and 552.2, respectively; P=NS) (Supplemental Figure 1B) .
Discussion
CD160 is a cysteine-rich, glycosylphosphatidylinositol-linked membrane protein with a single Ig-like domain and has weak homology to the firstIg-C2 domain of NK receptor, KIR2DL4: 22% identity and 44% similarity. 5 CD160 has a broad specificity for both classical and non-classical MHC class I molecules 10 and is a ligand for herpes virus entry mediator (HVEM). The "aberrant" expression of many proteins in CLL has been described -such as, the pan T-cell marker CD5 and the TCR-signal transduction molecule, ZAP-70, 16, 17 initially described exclusively in T-cells and NK cells. 18 The recruitment and phosphorylation of Syk/ZAP-70 tyrosine kinases to the TCR allows differentiation and proliferation. 30, 31 Similar responses were shown in ZAP-70 expressing CLL cells, with enhanced signal transduction by the BCR. 32 In the B-cell lineage, ZAP-70 was initially thought to be a tumor-specific antigen, but subsequent work found that ZAP-70 is not specific to malignant B-cells, but is also expressed in activated normal human B-cells, 22 naïve, germinal centre, memory, cord blood cells and peripheral blood B-cells. 23 Unlike ZAP-70, CD160 expression in malignant B-cells appears to be truly "aberrant" and we have exploited this to look at its expression profile and diagnostic utility in acute and chronic B-cell malignancies. In a test cohort of 811 cases,
CD160 expression was almost universal in CLL and HCL. This was confirmed in a validation cohort of
163 B-LPDs. Lymph node and splenic tissue from patients with CLL and HCL were also CD160 positive. Diagnostic immunophenotyping of B-LPDs requires a panel of MoAbs, with an ever increasing range of target antigens proposed to help differentiate between the different diseases. [33] [34] [35] [36] However, the disease-specific CD5/CD23/CD160 combination allowed a simplified "mini CLL score" to be derived from the single tube CD160FCA assay. A mini score of 3 differentiated CLL from other B-LPD, with a very high diagnostic odds ratio of 1430 (542-3772), a PPV and NPV of 99% and 94%, respectively; while a score of 0 excluded CLL, MCL and HCL. However, biological heterogeneity includes rare CD23-negative cases of CLL, while CD23 positivity in MCL is not uncommon. [26] [27] [37] [38] In our test and validation cohorts, 13/42 (31%) cases of MCL in leukemic phase were CD23 + , while 5 MCL cases in the test cohort had a mini CLL score of 3. The diagnostic discriminant was useful in such cases with an atypical immunophenotype by combining the information from the CD160FCA on the mini CLL score and the level of CD23 expression ( Figure 5C ). In the validation cohort, the diagnostic discriminant-(mini score x CD23r) -was ≥ 0.50 in all CLL cases and differentiated CLL from leukemic CD23 + MCL and other CD5 + B-LPD (P<0.0001) ( Figure 5C ). We propose the addition of anti-CD160 MoAb to existing diagnostic panels, with the diagnostic discriminant giving an additional robust, numerical summation of immunophenotypic data to aid in the diagnosis of B-LPD, particularly cases that are immunologically atypical. Our data suggests a simpler scoring system than both historical and current systems in place. 39, 40 Other molecules have recently been reported to show CLL-restricted expression, including the tumor associated antigen Receptor tyrosine-kinase Orphan Receptor 1 (ROR1) 41 and CD200. 36, 42 ROR1 mRNA and surface protein were found to be strongly expressed in MCL, as well as positivity in marginal zone lymphoma, B-ALL and a subset of normal Bcell precursors. 43, 44 CD200 has an expression profile including CD19+ B-cells (normal and malignant),
T-cell blasts, follicular dendritic cells, thymocytes, neural tissue and endothelium. 45 Despite its expression in normal tissue, CD200 is up-regulated in CLL resulting in a down-regulation of the Th1 immune response. 42 The weak or absent of expression of CD200 in MCL has been clinically useful in the differentiation between CLL and MCL. Secondary lymphoid organs -splenic and tonsillar material).
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